Benefits
Gas-related digestive symptoms in healthy adults
In 76 healthy adults with gas-related symptoms, 2 billion CFU of BS50 a day for 6 weeks raised the share who improved on a combined bloating, burping and flatulence score, the registered main outcome, to 47.4 versus 22.2 percent on placebo. BIO-CAT funded the trial and took part in its design and writing.
Burping, bloating and other single symptoms
Of the single symptoms in the same trial, only burping improved more than on placebo (44.7 versus 22.2 percent, p = .041). Bloating did not reach significance (31.6 versus 13.9 percent, p = .071), and nausea, cramping, stomach rumbling, reflux, bowel habits and stool consistency did not differ.
Blood tests, sleep and other measured outcomes
Over the 6 week trial, blood chemistry, blood counts, lipids, gut permeability markers and inflammation markers showed no clinically meaningful changes, and sleep quality did not change. Respiratory infections were planned as an outcome, but too few occurred to compare the groups.
Mechanism of action
Spore form
BS50 is taken as dormant spores. A review of Bacillus probiotics describes spores as heat stable and able to survive the stomach. Whether BS50 spores germinate in the human gut has not been measured; the trial authors point to a study of a different strain, DE111, whose spores germinated in the small intestine within 3 hours.
Enzymes and antimicrobial genes
The trial paper reports that BS50 cells secreted digestive enzymes in lab tests, and its authors propose that enzymes released in the gut could reduce fermentation and gas, while stating that the mechanism is unknown. The BS50 genome carries gene clusters for antimicrobial compounds such as fengycins, which the authors suggest may help balance gut bacteria; this was not tested in people.
Clinical trials
Randomized, double-blind, placebo-controlled parallel trial at one site (Biofortis Research, Addison, Illinois), July to November 2021; one capsule of 2 billion CFU BS50 or maltodextrin placebo daily with the largest meal for 6 weeks; registered NCT05004454 with bloating, flatulence and burping as the primary outcome; funded by BIO-CAT, whose employees were two of five authors; the funders took part in design, writing and the decision to publish, and BIO-CAT Microbials filed a related patent application (Garvey et al. 2022, Gut Microbes)
76 healthy adults aged 30 to 65 (38 per group, average age about 50) with a combined bloating, burping and flatulence score of 3 or more in the baseline week.
Primary outcome met: 47.4 percent on BS50 versus 22.2 percent on placebo improved on the combined bloating, burping and flatulence score (OR 3.2, 95% CI 1.1 to 8.7, p = .024). Burping alone improved more than on placebo (44.7 versus 22.2 percent, p = .041); bloating did not reach significance (31.6 versus 13.9 percent, p = .071), and other symptoms, bowel habits and stool consistency did not differ. Blood tests showed no clinically meaningful changes.
Genome screening for toxin, virulence, secondary metabolite and antibiotic resistance genes, antibiotic MIC testing against eight antibiotics, and tests of BS50 cell lysates on cultured human Caco-2 cells; funded by BIO-CAT, whose employees were three of four authors and which took part in design, analysis and writing (Brutscher et al. 2022, Microorganisms)
No people: the BS50 genome, BS50 cells and cultured Caco-2 cells.
No known Bacillus toxin genes were found. BS50 was susceptible to seven of eight antibiotics and resistant to streptomycin, and no resistance gene sat within a complete mobile genetic element. BS50 lysates did not reduce Caco-2 cell viability or monolayer permeability. Lab data only; it does not measure long-term use in people.